Kidney cancer drugs have been developed for treating renal cell carcinoma (RCC), which is the most common type of kidney cancer in adults. These drugs include vascular endothelial growth factor (VEGF) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, and checkpoint inhibitors. VEGF inhibitors help stop or slow tumor growth by preventing the formation of new blood vessels required for tumor growth. mTOR inhibitors work by preventing mTOR, which is a protein in cells that helps them grow, divide, and survive, from executing certain functions. Checkpoint inhibitors help boost the immune system’s ability to detect and destroy cancer cells. The rise in application of immunotherapy such as checkpoint inhibitors for kidney cancer treatment is driving market growth.
The Global Kidney Cancer Drugs Market Demand is estimated to be valued at US$ 7.15 Bn in 2024 and is expected to exhibit a CAGR of 9.7% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the Kidney Cancer Drugs are Celanese Corporation, British Petroleum, Eastman Chemical Company, Jiangsu Sopo (Group) Co., Ltd., China Petroleum & Chemical Corporation (Sinopec), Lyondell Basell Industries, Saudi Basic Industries Corporation (SABIC), Mitsubishi Chemical Company, PetroChina Co. Ltd., PetroChina Co. Ltd., BASF SE.
Key opportunities in the market include potential approval and launch of new drugs, rise in R&D investment for developing novel therapeutics, and growing focus on precision medicine.
The rise in application of immunotherapy has provided new hope for treatment of advanced RCC as compared to conventional chemotherapies. Drugs such as nivolumab, pembrolizumab, and avelumab used for checkpoint inhibition have shown promising results.
Market Drivers
A key driver for the kidney cancer drugs market is the rising prevalence of kidney cancer. Around 403,262 new cases of kidney cancer are diagnosed and 175,098 deaths occur each year globally. The risk factors such as obesity, smoking, genetic factors, and occupational exposure contribute to the increasing incidence of kidney cancer. This high prevalence creates robust demand for effective treatment drugs such as targeted therapies and immunotherapies in the market.
Current Challenges in Kidney Cancer Drugs Market
The kidney cancer drugs market is facing several challenges currently. The high cost of targeted drugs and immunotherapies is putting financial pressure on patients as well as healthcare systems. Additionally, the fact that kidney cancer is usually asymptomatic in early stages leads to late diagnosis in many cases. This reduces the efficacy of available treatment options. Research efforts are ongoing to develop more affordable and effective drugs. However, bringing a new drug to the market is an expensive and lengthy process which poses challenges.
SWOT Analysis
Strength: Growing R&D investments from major players to develop novel targeted therapies and immunotherapies.
Weakness: High cost of newer drugs limits widespread access and adoption.
Opportunity: Developing regions with growing diagnosis rates represent emerging markets.
Threats: Patent cliff of blockbuster drugs poses pricing and competition risks.
Geographical Regions
North America currently accounts for the major share of the global kidney cancer drugs market in terms of value. This is attributed to factors such as the high diagnosis and treatment rates in the region. According to estimates, the US market for kidney cancer drugs was worth over US$ 3 Bn in 2021.
The Asia Pacific region is projected to be the fastest growing market during the forecast period from 2024 to 2030. This can be credited to rising healthcare expenditure, growing incidence of renal cell carcinoma, and increasing access to advanced treatment options in major countries such as China and India.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
